simeprevir

(redirected from Olysio)
Also found in: Medical.
Translations

simeprevir

n simeprevir m
References in periodicals archive ?
In collaboration with Medivir AB, Janssen subsequently developed and launched the second generation protease inhibitor OLYSIO (simeprevir), which is approved in countries around the world.
The rack rate of Sovaldi is typically around $84,000, while the rack rate of another breakthrough hepatitis C drug, Olysio, is around $66,000.
OLYSIO /SOVRIAD Hep C sales were down 73% in the quarter to $21 million.
However, Sovaldi costs $84,000 for a course of treatment and Olysio costs $76,000, for a total cost of $160,000.
She wound up paying only about $100 for a course of treatment involving Sovaldi and the Johnson & Johnson drug Olysio that essentially cured her.
The agency cleared Olysio (simeprevir) in November 2013, Sovaldi (sofosbuvir) in December 2013 and Harvoni (ledipasvir and sofosbuvir) in October 2014.
Medivir AB, Stockholm, Sweden, announced the US FDA has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) for the use of once-daily Olysio (simeprevir) in combination with sofosburvir for 12 weeks treatment of adult patients wit genetype 1 chronic hepatitis C.
s Olysio (simeprevir) as a hepatitis C treatment and is expected to approve a similar new drug, solos-buvir, later this year.
According to the company, discontinuation of development of JNJ-4178 does not affect the ongoing partnership with Janssen on Olysio (simeprevir), or the existing licensing agreement with Janssen in which simeprevir is included.
Olysio is nearly as expensive as Sovaldi, costing roughly $66,000 for a 12-week treatment course.
And, according to a Kaiser Health News report, a California panel made similar recommendations, saying in a report to insurers, providers and consumers that immediate treatment with the new drugs, Sovaldi and Olysio, should be given to those with advanced disease but could be delayed for others.
United States-based Janssen Therapeutics has submitted a supplemental new drug application to the US Food and Drug Administration to update the label for once-daily, all-oral Olysio (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, it was reported on Friday.